From grimoire
Creates a gestational-age–based prenatal genetic screening plan: NIPT, NT ultrasound, serum screens, quad screen, CVS, amniocentesis, GBS screening.
How this skill is triggered — by the user, by Claude, or both
Slash command
/grimoire:design-prenatal-genetic-screening-planThe summary Claude sees in its skill listing — used to decide when to auto-load this skill
Map the sequence of genetic screening and diagnostic options across pregnancy.
Map the sequence of genetic screening and diagnostic options across pregnancy.
Adopted by: ACOG, SMFM, ACMG — offer all pregnant patients the full menu of screening/diagnostic options at the first visit. Impact: cfDNA/NIPT detects trisomy 21 with 99% sensitivity and 99.9% specificity (Palomaki et al., Genet Med 2011) vs. 80% for serum quad screen. Structured genetic counseling increases informed decision-making and reduces unnecessary invasive testing (Bernhardt et al., 2013). Why best: Patients cannot make informed decisions without a structured menu. Timing windows are narrow — missing them forecloses options.
Low-risk 28-year-old: NIPT at 12 weeks → anatomy scan at 19 weeks → GBS at 36 weeks. High-risk (prior trisomy 21, age 38): NIPT + NT at 12 weeks; consider amniocentesis; detailed anatomy scan at 20 weeks; echocardiogram at 22 weeks.
Health Disclaimer: Genetic screening decisions are deeply personal and involve complex medical, ethical, and personal considerations. Genetic counseling is strongly recommended before any diagnostic procedure.
npx claudepluginhub jeffreytse/grimoire --plugin grimoireMaps a full prenatal visit schedule with tests, screenings, and decisions by week. Use for OB/midwife visit cadence planning during pregnancy.
Searches 12+ authoritative clinical guideline sources (NICE, WHO, NCCN, AHA, ADA, SIGN, USPSTF, IDSA, ESMO, ESC, EASL) for evidence-graded treatment recommendations, dosing protocols, and screening guidance with source prioritization.
Generates clinical decision support documents for pharmaceutical research: biomarker-stratified cohort analyses with survival statistics, GRADE-graded treatment recommendations, and publication-ready LaTeX/PDF output.